No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
NXTC NextCure
- 0.970
- +0.020+2.11%
Close Dec 20 16:00 ET
- 0.970
- 0.0000.00%
Post 16:09 ET
27.17MMarket Cap-0.46P/E (TTM)
0.989High0.930Low54.80KVolume0.930Open0.950Pre Close52.84KTurnover0.30%Turnover RatioLossP/E (Static)28.01MShares2.57052wk High0.36P/B17.51MFloat Cap0.87052wk Low--Dividend TTM18.06MShs Float109.000Historical High--Div YieldTTM6.16%Amplitude0.870Historical Low0.964Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | NextCure Announces Acceptance of Ind Application for Lncb74
NextCure Announces Acceptance of IND Application for LNCB74
Piper Sandler Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $3
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
NextCure Highlights Presentation Of Data Demonstrating That NC605 Resulted In Enhanced Generation Of Quality Bone With Better Mechanical Properties
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone With Better Mechanical Properties in Mice With Moderate-to-Severe Osteogenesis Imperfecta
Heat List
US
Overall
Symbol
Price
% Chg
No Data